Cash-rich Synageva nets $147.7m from another stock sale
This article was originally published in Scrip
Executive Summary
Synageva BioPharma is taking advantage of its surging stock price to raise cash for the fourth time since the beginning of 2012 even though it appears that the rare disease drug developer has three years worth of cash on its balance sheet.